Aerovate Therapeutics Inc
NASDAQ:AVTE

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:AVTE
Watchlist
Price: 2.63 USD -1.13%
Market Cap: 75.9m USD
Have any thoughts about
Aerovate Therapeutics Inc?
Write Note

Aerovate Therapeutics Inc
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aerovate Therapeutics Inc
Operating Expenses Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Aerovate Therapeutics Inc
NASDAQ:AVTE
Operating Expenses
-$81.4m
CAGR 3-Years
-109%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Expenses
-$21.9B
CAGR 3-Years
-4%
CAGR 5-Years
-12%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Operating Expenses
-$11.2B
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
-8%
Amgen Inc
NASDAQ:AMGN
Operating Expenses
-$13.4B
CAGR 3-Years
-8%
CAGR 5-Years
-8%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Expenses
-$4.9B
CAGR 3-Years
-10%
CAGR 5-Years
-16%
CAGR 10-Years
-15%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Expenses
-$7.8B
CAGR 3-Years
-23%
CAGR 5-Years
-16%
CAGR 10-Years
-17%

See Also

What is Aerovate Therapeutics Inc's Operating Expenses?
Operating Expenses
-81.4m USD

Based on the financial report for Dec 31, 2023, Aerovate Therapeutics Inc's Operating Expenses amounts to -81.4m USD.

What is Aerovate Therapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 3Y
-109%

Over the last year, the Operating Expenses growth was -53%. The average annual Operating Expenses growth rates for Aerovate Therapeutics Inc have been -109% over the past three years .

Back to Top